ArticleBMJ open2026
Remote personalised exercise in axial spondyloarthritis: the SPARK trial - protocol for a 6-month randomised controlled trial.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06462937 (The SPARK Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The SPARK Trial: a Digital Exercise Intervention in Patients With Spondyloarthritis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurrent international guidelines recommend exercise as a first-line treatment of axial spondyloarthritis (SpA). However, there is no consensus on the mode and volume required to effectively reduce disease activity. It is advised that exercise for patients with SpA align with recommendations for the general population. For exercise to be sustainable and beneficial, it must be integrated into daily life and strategies to ensure long-term commitment are essential. The SpA Kardio (SPARK) trial aims to assess the impact of a remote, individually tailored exercise programme in patients with SpA with the proportion of patients reaching Axial Spondyloarthritis Disease Activity Score (ASDAS) inactive at 3 months as the primary outcome. The exercise includes high-intensity cardiorespiratory intervals and muscle strength exercises, with digital follow-up and monitoring, in patients with SpA. The SPARK programme includes regular supervision, personalised follow-up, goal-setting and education delivered through an application available on smartphones or tablets. METHODS AND ANALYSIS: The SPARK trial is a randomised controlled superiority trial. Individuals recently diagnosed with SpA by a rheumatologist with disease activity measured by the ASDAS ≥1.3 who have not used biological disease-modifying antirheumatic drugs (bDMARDs) are eligible for inclusion. Consenting individuals will be randomised to treatment as usual (n=130) or the SPARK programme (n=130) with 12-week duration. After 12 weeks, all participants will be rerandomised to either a supervised or an unsupervised SPARK programme for weeks 12-24. The primary outcome will be achievement of an inactive disease state (ASDAS <1.3) at week 12 in each group. Secondary outcomes include use of medication (bDMARDs and non-steroidal anti-inflammatory drugs (NSAIDs)), cardiorespiratory fitness, muscle strength, sleep quality and quantity, health-related quality of life, work participation, adverse events and disease activity at week 24 (ASDAS and the Bath Ankylosing Spondylitis Disease Activity Index). MRI of the lumbar spine and sacroiliac joints at baseline and full-body dual-energy X-ray absorptiometry will be performed in a subgroup. ETHICS AND DISSEMINATION: The SPARK trial is approved by Regional Committee for Medical and Health Research Ethics in South-Eastern Norway (#684555). The SPARK trial will contribute important knowledge on effects of a tailored digital exercise programme with monitored remote follow-up in patients with SpA and may improve the initial care of patients in terms of disease activity and ensure use of bDMARDs according to modern guidelines. TRIAL REGISTRATION NUMBER: NCT06462937.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.